Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure

Thomas Prébet, Steven D. Gore, Benjamin Esterni, Claude Gardin, Raphael Itzykson, Sylvain Thepot, Franco̧is Dreyfus, Odile Beyne Rauzy, Christian Recher, Lionel Ades̀, Bruno Quesnel, C. L. Beach, Pierre Fenaux, Norbert Vey

Research output: Contribution to journalArticle

Abstract

Purpose: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described. Patients and Methods: Overall, 435 patients with high-risk MDS and former refractory anemia with excess blasts in transformation (RAEB-T) were evaluated for outcome after AZA failure. The cohort of patients included four data sets (ie, AZA001, J9950, and J0443 trials and the French compassionate use program). Results: The median follow-up after AZA failure was 15 months. The median overall survival was 5.6 months, and the 2-year survival probability was 15%. Increasing age, male sex, high-risk cytogenetics, higher bone marrow blast count, and the absence of prior hematologic response to AZA were associated with significantly worse survival in multivariate analysis. Data on treatment administered after AZA failure were available for 270 patients. Allogeneic stem-cell transplantation and investigational agents were associated with a better outcome when compared with conventional clinical care. Conclusion: Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.

Original languageEnglish (US)
Pages (from-to)3322-3327
Number of pages6
JournalJournal of Clinical Oncology
Volume29
Issue number24
DOIs
StatePublished - Aug 20 2011

Fingerprint

Azacitidine
Myelodysplastic Syndromes
Treatment Failure
Survival
Compassionate Use Trials
Refractory Anemia with Excess of Blasts
Unsafe Sex
Stem Cell Transplantation
Standard of Care
Lymphocyte Activation
Cytogenetics
Multivariate Analysis
Bone Marrow
Clinical Trials
Population

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prébet, T., Gore, S. D., Esterni, B., Gardin, C., Itzykson, R., Thepot, S., ... Vey, N. (2011). Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure. Journal of Clinical Oncology, 29(24), 3322-3327. https://doi.org/10.1200/JCO.2011.35.8135

Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure. / Prébet, Thomas; Gore, Steven D.; Esterni, Benjamin; Gardin, Claude; Itzykson, Raphael; Thepot, Sylvain; Dreyfus, Franco̧is; Rauzy, Odile Beyne; Recher, Christian; Ades̀, Lionel; Quesnel, Bruno; Beach, C. L.; Fenaux, Pierre; Vey, Norbert.

In: Journal of Clinical Oncology, Vol. 29, No. 24, 20.08.2011, p. 3322-3327.

Research output: Contribution to journalArticle

Prébet, T, Gore, SD, Esterni, B, Gardin, C, Itzykson, R, Thepot, S, Dreyfus, F, Rauzy, OB, Recher, C, Ades̀, L, Quesnel, B, Beach, CL, Fenaux, P & Vey, N 2011, 'Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure', Journal of Clinical Oncology, vol. 29, no. 24, pp. 3322-3327. https://doi.org/10.1200/JCO.2011.35.8135
Prébet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S et al. Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure. Journal of Clinical Oncology. 2011 Aug 20;29(24):3322-3327. https://doi.org/10.1200/JCO.2011.35.8135
Prébet, Thomas ; Gore, Steven D. ; Esterni, Benjamin ; Gardin, Claude ; Itzykson, Raphael ; Thepot, Sylvain ; Dreyfus, Franco̧is ; Rauzy, Odile Beyne ; Recher, Christian ; Ades̀, Lionel ; Quesnel, Bruno ; Beach, C. L. ; Fenaux, Pierre ; Vey, Norbert. / Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 24. pp. 3322-3327.
@article{1717afb14a944cc8aaaee3ebaef6a5ce,
title = "Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure",
abstract = "Purpose: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described. Patients and Methods: Overall, 435 patients with high-risk MDS and former refractory anemia with excess blasts in transformation (RAEB-T) were evaluated for outcome after AZA failure. The cohort of patients included four data sets (ie, AZA001, J9950, and J0443 trials and the French compassionate use program). Results: The median follow-up after AZA failure was 15 months. The median overall survival was 5.6 months, and the 2-year survival probability was 15{\%}. Increasing age, male sex, high-risk cytogenetics, higher bone marrow blast count, and the absence of prior hematologic response to AZA were associated with significantly worse survival in multivariate analysis. Data on treatment administered after AZA failure were available for 270 patients. Allogeneic stem-cell transplantation and investigational agents were associated with a better outcome when compared with conventional clinical care. Conclusion: Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.",
author = "Thomas Pr{\'e}bet and Gore, {Steven D.} and Benjamin Esterni and Claude Gardin and Raphael Itzykson and Sylvain Thepot and Franco̧is Dreyfus and Rauzy, {Odile Beyne} and Christian Recher and Lionel Ades̀ and Bruno Quesnel and Beach, {C. L.} and Pierre Fenaux and Norbert Vey",
year = "2011",
month = "8",
day = "20",
doi = "10.1200/JCO.2011.35.8135",
language = "English (US)",
volume = "29",
pages = "3322--3327",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "24",

}

TY - JOUR

T1 - Outcome of high-risk myelodysplastic syndrome after azacitidine Treatment failure

AU - Prébet, Thomas

AU - Gore, Steven D.

AU - Esterni, Benjamin

AU - Gardin, Claude

AU - Itzykson, Raphael

AU - Thepot, Sylvain

AU - Dreyfus, Franco̧is

AU - Rauzy, Odile Beyne

AU - Recher, Christian

AU - Ades̀, Lionel

AU - Quesnel, Bruno

AU - Beach, C. L.

AU - Fenaux, Pierre

AU - Vey, Norbert

PY - 2011/8/20

Y1 - 2011/8/20

N2 - Purpose: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described. Patients and Methods: Overall, 435 patients with high-risk MDS and former refractory anemia with excess blasts in transformation (RAEB-T) were evaluated for outcome after AZA failure. The cohort of patients included four data sets (ie, AZA001, J9950, and J0443 trials and the French compassionate use program). Results: The median follow-up after AZA failure was 15 months. The median overall survival was 5.6 months, and the 2-year survival probability was 15%. Increasing age, male sex, high-risk cytogenetics, higher bone marrow blast count, and the absence of prior hematologic response to AZA were associated with significantly worse survival in multivariate analysis. Data on treatment administered after AZA failure were available for 270 patients. Allogeneic stem-cell transplantation and investigational agents were associated with a better outcome when compared with conventional clinical care. Conclusion: Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.

AB - Purpose: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described. Patients and Methods: Overall, 435 patients with high-risk MDS and former refractory anemia with excess blasts in transformation (RAEB-T) were evaluated for outcome after AZA failure. The cohort of patients included four data sets (ie, AZA001, J9950, and J0443 trials and the French compassionate use program). Results: The median follow-up after AZA failure was 15 months. The median overall survival was 5.6 months, and the 2-year survival probability was 15%. Increasing age, male sex, high-risk cytogenetics, higher bone marrow blast count, and the absence of prior hematologic response to AZA were associated with significantly worse survival in multivariate analysis. Data on treatment administered after AZA failure were available for 270 patients. Allogeneic stem-cell transplantation and investigational agents were associated with a better outcome when compared with conventional clinical care. Conclusion: Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.

UR - http://www.scopus.com/inward/record.url?scp=80051992418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051992418&partnerID=8YFLogxK

U2 - 10.1200/JCO.2011.35.8135

DO - 10.1200/JCO.2011.35.8135

M3 - Article

C2 - 21788559

AN - SCOPUS:80051992418

VL - 29

SP - 3322

EP - 3327

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 24

ER -